Potassium Phosphates Injection, Solution
NDC Package 0517-2102-25

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Potassium Phosphates (potassium phosphate) injection is potassium Phosphates Injection is indicated as a source of phosphorus:in intravenous fluids to correct hypophosphatemia in adults and pediatric patients when oral or enteral replacement is not possible, insufficient or contraindicated.for parenteral nutrition in adults and pediatric patients when oral or enteral nutrition is not possible, insufficient or contraindicated. This formulation utilizes a injection, solution delivery system. Marketed by American Regent, Inc., this product is identified by NDC 0517-2102 and is authorized under FDA application ANDA216274.

Identification & Billing

NDC Package Code
0517-2102-25
Package Description
25 VIAL, SINGLE-DOSE in 1 TRAY / 15 mL in 1 VIAL, SINGLE-DOSE (0517-2102-01)
Product Code
0517-2102
11-Digit Billing Format
00517210225
RxNorm Crosswalk
  • RxCUI: 1928567 - potassium phosphates (phosphorus 15 MMOL / potassium 22 MEQ) in 5 ML Injection
  • RxCUI: 1928567 - 5 ML dibasic potassium phosphate 236 MG/ML / monobasic potassium phosphate 224 MG/ML Injection
  • RxCUI: 1928567 - 5 ML Dibasic K+ phosphate 236 MG/ML / Monobasic K+ phosphate 224 MG/ML Injection
  • RxCUI: 1928567 - 5 ML Dibasic Pot phosphate 236 MG/ML / Monobasic Pot phosphate 224 MG/ML Injection
  • RxCUI: 1928567 - phosphorus 15 MMOL / potassium 22 MEQ per 5 ML Injection

Clinical Specifications

Proprietary Name
Potassium Phosphates
Non-Proprietary Name
Potassium Phosphate
Substance Name
Potassium Phosphate, Dibasic; Potassium Phosphate, Monobasic
Dosage Form
Injection, Solution - A liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection.
Administration Route
Intravenous - Administration within or into a vein or veins.
Active Ingredient(s)
Pharmacologic Class
Usage Information
Potassium Phosphates Injection is indicated as a source of phosphorus:in intravenous fluids to correct hypophosphatemia in adults and pediatric patients when oral or enteral replacement is not possible, insufficient or contraindicated.for parenteral nutrition in adults and pediatric patients when oral or enteral nutrition is not possible, insufficient or contraindicated.

Regulatory & Marketing

Labeler Name
American Regent, Inc.
Product Type
Human Prescription Drug
FDA Application #
ANDA216274
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
10-13-2023
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0517-2102-25 identifies a specific commercial package of 25 vial, single-dose in 1 tray / 15 ml in 1 vial, single-dose (0517-2102-01) of Potassium Phosphates, a human prescription drug labeled by American Regent, Inc.. This injection, solution is formulated for intravenous use and contains potassium phosphate, dibasic; potassium phosphate, monobasic as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by American Regent, Inc. on October 13, 2023. The current certification is valid through December 31, 2026.

How is this American Regent, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00517210225. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0517-2102-25
11-Digit CMS (5-4-2)
00517-2102-25

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.